Innate Pharma (IPHA) Return on Capital Employed (2021 - 2025)
Innate Pharma posted quarterly Return on Capital Employed of 377.03% for Q4 2025, down 28618.0% year-on-year from N/an in Q4 2024, and down 138.41% on a QoQ basis from 158.15% in Q2 2025.
Innate Pharma (IPHA) has 5 years of Return on Capital Employed data on file, last reported at 377.03% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 28618.0% year-over-year to 377.03%; the trailing twelve-month figure through Dec 2025 stood at 377.03% (down 28618.0% YoY), and the FY2025 full-year result was 118.21%, down 7164.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 377.03%, down from 158.15% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 13.42% in Q2 2021 and bottomed at 377.03% in Q4 2025.
- The 5-year median for Return on Capital Employed is 29.49% (2021), against an average of 88.06%.
- The widest annual swing landed in 2022, when Return on Capital Employed surged 311 bps; it then sank 28618 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 29.49% in 2021, then advanced by 11 bps to 26.37% in 2022, then slumped by 55 bps to 40.84% in 2023, then tumbled by 122 bps to 90.85% in 2024, then tumbled by 315 bps to 377.03% in 2025.
- The last three Return on Capital Employed figures came in at 377.03% (Q4 2025), 158.15% (Q2 2025), and 90.85% (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 21.10% |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 10.19% |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 20.34% |
| 10 | Innate Pharma | 199.64 Mn | 199.64 Mn | - | -377.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -377.03% |
| Jun 30, 2025 | -158.15% |
| Dec 31, 2024 | -90.85% |
| Jun 30, 2024 | -28.93% |
| Dec 31, 2023 | -40.84% |
| Jun 30, 2023 | -27.50% |
| Dec 31, 2022 | -26.37% |
| Dec 31, 2021 | -29.49% |
| Jun 30, 2021 | -13.42% |